Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=2&sort=other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators" }, "data": [ { "type": "Grant", "id": "15202", "attributes": { "award_id": "1R56AI178166-01A1", "title": "Pathogenesis and Outcomes of SARS-CoV-2 In Utero Transmission - Immunologic and Virologic Evaluations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6243, "first_name": "BROOKE ALLISON", "last_name": "Bozick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": "2025-08-31", "award_amount": 664837, "principal_investigator": { "id": 31785, "first_name": "Andrea A.Z.", "last_name": "Kovacs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 152, "ror": "https://ror.org/03taz7m60", "name": "University of Southern California", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Importance: Despite effective vaccines, SARS-CoV-2 infection remains a major public health problem for pregnant women and their newborns as they have increased morbidity and mortality. Studies on estimated rates of in utero transmission are conflicting and reported on small numbers mostly limited to PCR testing at birth. Critical Gaps include limited diagnostics to identify in utero infection and lack of understanding of factors that impact MTCT and the pathogenesis of disease. From October 2021 through February 2023, we studied 1294 infant cord bloods for presence and level of SARS-CoV-2 antibodies. Overall, 89.9% had anti-RBD IgG, indicating maternal vaccination and/or previous infection and 55.1% had both anti-N and anti-RBD IgG, indicative of past infection. Fetal IgA and/or IgM antibodies to SARS-CoV-2 were found in 21.8% of 176/808 samples with anti-N, indicative of in utero transmission. The overall goal of this study is to identify newborns with in utero SARS-CoV-2 and prospectively follow infants to identify clinical and neurodevelopment outcomes. Aim 1: Identify newborns with in utero SARS-CoV-2 infection using a multi-faceted approach and assess relationship with inflammation, placental infection and pathology, and immunity. Hypothesis 1: In utero infection will be associated with elevated soluble markers of inflammation in newborn cord blood and evidence of placental infection and dysfunction. Using cord blood we will screen 3,600 newborns for anti-N, S, and RBD IgG antibodies (Abs) and if anti-N+ we will assess for SARS-CoV-2 specific anti-IgM and anti-IgA abs. Maternal SARS-CoV-2 qPCR testing will be done at delivery, and if qPCR+, newborn qPCR will be performed at 24/48 hours. Variant type will be determined by ddPCR. Newborn meconium/stool samples will have qPCR testing. Soluble biomarkers of inflammation and immune activation will be determined. Finally, placentas will be evaluated for pathology and SARS-CoV-2 infection. Aim 2. Longitudinally assess for immune activation, dysregulation, and function among a subset of infants with in utero infection and matched controls. Hypothesis 2: In utero infected infants will have abnormal markers of inflammation, immune activation, and dysregulation that if sustained will be associated with adverse clinical outcomes. In a subset of 100 infants with in utero SARS-CoV-2 and 50 uninfected controls we will determine levels of CD4 and CD8 T-cell activation and dysregulation and assess for SARS-CoV-2 specific antibodies and T cell response in mother-infant dyads at birth and longitudinally. We will then correlate with clinical and neurodevelopmental outcomes. At the end of this project, we will have developed a comprehensive algorithm to screen and follow newborns with in-utero SARS-CoV-2 and will have determined if there are immunologic dysfunctions impacting clinical, developmental, neurologic, and other abnormalities that may require long-term follow-up, treatments and/or interventions.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15283", "attributes": { "award_id": "1R21AI184087-01A1", "title": "In vivo innate immune sensing of HIV-1 infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24689, "first_name": "Uday K.", "last_name": "Shankar", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2026-06-30", "award_amount": 231752, "principal_investigator": { "id": 31871, "first_name": "ANTHONY", "last_name": "RONGVAUX", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2062, "ror": "", "name": "FRED HUTCHINSON CANCER CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "SUMMARY/ABSTRACT HIV-1 remains a major public health challenge worldwide, with 1.3 million new infections and over 600,000 AIDS- related deaths in 2022. An effective vaccine that confers long-term protection against infection would be an essential tool in eradicating AIDS, but all vaccine candidates have been largely unsuccessful to date. This is due to the unique biology of the virus and its extraordinary ability to escape immune responses. The immune events immediately following HIV-1 transmission have critical impacts on the ensuing disease course, but the underlying biology has proven difficult to detail. Overall, the innate immune response to a viral infection can establish a state of viral resistance and contribute to controlling virus replication, but it also induces inflammation that can favor viral spread, immunopathology and disease progression. Studies of prospective cohorts of volunteers at high risk of contracting HIV-1 have revealed the sequence of events during acute infection, including the cytokine storm induced by the innate immune responses. Mechanistic in vitro studies have demonstrated the capacity of diverse innate immune sensors to detect HIV-1 and induce cytokine production. However, the relative contribution of each innate immune cell type and sensing pathway following in vivo HIV-1 infection, and their functional impact on both the virus and the host, are largely unknown. To overcome this limitation, we developed the MISTRG model of mice repopulated with a complete human immune system (“humanized mice”), including monocytes, macrophages, dendritic cells and NK cells that are essential to mounting innate immune responses. MISTRG mice are permissive for HIV-1 infection and recapitulate several aspects of the immune responses observed in humans, including the cytokine storm triggered in the first few weeks after infection. Furthermore, we have recently developed a highly efficient protocol to knockout genes from the human immune system of MISTRG mice, providing genetic tools that were previously exclusive to conventional mouse models. Using the innovative MISTRG model, we now plan to investigate the fundamental in vivo mechanisms of the innate immune response to HIV-1, following infection through both intravenous and mucosal routes. First, we will identify the cellular source of cytokines that are released during the acute phase of HIV-1 infection. We will complement these descriptive studies with functional depletion experiments, to determine how each cytokine-producing cell type affects the virus and the infected host. Second, we will use gene knockout approaches to determine the functional roles of membrane-bound versus intracellular innate immune sensors in the response to HIV-1. We hypothesize that different cell types contribute to HIV-1 sensing in vivo, that they rely on distinct sensors to do so, and that their concerted responses functionally impact the course of disease. Our findings will address a significant knowledge gap, and may inform the rationale design of novel innate immune interventions for the prevention or therapy of HIV-1/AIDS.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15210", "attributes": { "award_id": "1G08LM014406-01", "title": "Long COVID Health Literacy Project: Bringing Health Information to Patients and Providers with Health Disparities in Rural Northern New England", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Library of Medicine (NLM)" ], "program_reference_codes": [], "program_officials": [ { "id": 31790, "first_name": "CRISTAN", "last_name": "SMITH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": "2027-07-10", "award_amount": 150000, "principal_investigator": { "id": 31791, "first_name": "Jeffrey", "last_name": "Parsonnet", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2072, "ror": "", "name": "DARTMOUTH-HITCHCOCK CLINIC", "address": "", "city": "", "state": "NH", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of this project is to address health disparities in the care of patients with post-acute COVID syndrome (PACS) due to the rural nature of northern New England and its shortage of medical services. We will develop useful, understandable and relatable information for patients and providers, in partnership with rural and biomedical libraries. The foundation for our project is the Dartmouth-Hitchcock PACS Clinic, an established, comprehensive clinic serving patients in Vermont and New Hampshire. The rural nature of northern New England poses a challenge to delivery of comprehensive care to PACS patients. Most parts of VT and NH are characterized as being “small town/isolated rural” or “large rural town.” The debilitating nature of PACS threatens job security, financial stability, and the ability to function normally, and there is limited access to primary care, physical therapy, occupational therapy, and mental health services that can accept and are familiar with the complex nature of PACS. Furthermore, the Area Deprivation Index (ADI), based on a measure created by HRSA, shows that at least half of the two states have ADI scores of >50, indicating that they are “disadvantaged” in relation to national standards. A large percentage of the 1300 patients referred to our PACS clinic report difficulties in accessing reliable information about managing their condition and finding locally based services. Affordable, high-speed internet service is often limited in rural settings, and many rely on local libraries to meet those needs. Above all, patients express a sense of isolation, both physical and emotional. Our experience has taught us that bridging that sense of isolation is often the greatest service we can provide. Our goal is to “reach more people in more ways through enhanced engagement pathways.” Our aims are: To improve the care of patients with PACS in rural VT and NH by disseminating useful, usable, and understandable information to this health-disparity population. To promote a better understanding of PACS for patients and providers by means of new, appropriately targeted resources. We will create an online archive of “digital stories” that highlight lived experiences of patients with PACS and create an independent website and monthly newsletter with content about PACS that is responsive to the emerging science and meets the needs of our patients and providers. To raise awareness about PACS in rural communities and promote community access to information about PACS and post-COVID care. We will partner with rural libraries, which are often a primary hub of information-sharing in rural communities, to assist in deploying computer and information technology that is otherwise unavailable or difficult to use for many of our patients. We will tailor information to meet the needs of our population. Our efforts should be generalizable to other rural communities in the US.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15290", "attributes": { "award_id": "1K01DA058152-01A1", "title": "Exploring the antecendents and consequences of cannabis use in the context of coping: An experimental study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 28174, "first_name": "JOHN RAPHAEL", "last_name": "Fedota", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 188039, "principal_investigator": { "id": 31880, "first_name": "Carillon Joy", "last_name": "Skrzynski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1583, "ror": "", "name": "UNIVERSITY OF COLORADO", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "As cannabis legalization increases, there have been concurrent increases in use. A common reason for use is the mitigation of anxiety and stress, which has been exacerbated with the COVID-19 pandemic. However, cannabis use for coping purposes is associated with greater quantity and frequency (Q/F) of cannabis use, increased risk for cannabis-related problems, and greater likelihood for cannabis dependence. In turn, greater Q/F of cannabis use and dependence can lead to safety risks, mental/physical health issues, and other problems like greater Q/F of alcohol use. Thus, developing a greater understanding of cannabis use for coping purposes is a critical research endeavor. There are several important avenues of research that can inform our understanding of this use pattern. The first is examining if quantity of cannabis is actually increased when used for coping purposes, which has not yet been experimentally tested, as well as exploring factors that may moderate this effect (e.g., social anxiety and inhibitory control). A second avenue is investigating whether cannabis use actually mitigates stress. A third avenue is exploring the biological role of the endocannabinoid system as a mechanism by which cannabis use may relate to acute stress reduction as well as the role of cannabinoid content in this process. Specifically, research shows that the endocannabinoid, arachidonoyl ethanolamide (AEA), is negatively associated with anxiety and stress such that it may mediate the relationship between cannabis use and stress reduction. Because the two main cannabis constituents, 9-delta tetrahydrocannabinol (THC) and cannabidiol (CBD), are associated with disparate effects on AEA, they may differentially influence how cannabis use relates to stress. In particular, CBD may actually decrease stress compared to THC via greater effects on AEA production. This study proposes to examine these research questions with four aims. The first will experimentally test a causal relationship between cannabis use for coping purposes and quantity of cannabis use (i.e., if more cannabis is used after stress induction compared to a control condition among individuals who endorse cannabis use for coping purposes). The second will test if the relationship between stress and cannabis use is stronger for individuals with social anxiety and/or poorer inhibitory control. The third will test if cannabis use after stress is related to decreases in subjective and objective stress. The fourth will ask whether decreases in stress are mediated via increased AEA, and if this indirect relationship is stronger with greater CBD to THC product ratios. Knowledge gained from this study will have significant public health impact including aiding in intervention and prevention efforts for cannabis misuse and contributing data on the harm reduction potential of CBD.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15314", "attributes": { "award_id": "1R41AT012854-01", "title": "A scalable intervention for stress management practices", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Complementary and Integrative Health (NCCIH)" ], "program_reference_codes": [], "program_officials": [ { "id": 31902, "first_name": "Emrin U", "last_name": "Horgusluoglu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-17", "end_date": "2025-08-31", "award_amount": 294312, "principal_investigator": { "id": 31903, "first_name": "Milton", "last_name": "Aguirre", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2531, "ror": "", "name": "LIVOTION LLC", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Roughly 60% of college students meet the criteria for at least one mental health disorder, with anxiety and depression being the most common diagnoses. The number of students seeking help for mental health issues increased by almost 40% at campus counseling centers between 2009 and 2015 and has continued to rise since the onset of the COVID-19 pandemic, yet the demand has not been proportionately matched with increased funding to support mental health provision on college campuses. Thus, college students require a different approach to managing the stress that exacerbates their mental health symptoms. Technology-based breathing interventions for stress management, which have been shown to prevent and remediate stress, are growing in popularity with the rise of commercially available mobile apps and bio-feedback technologies that do not require the help of a professional. However, while such mHealth interventions are now widely available, they often fail because they do not lend themselves to use in real-world settings. Most technology-based interventions require the use of mobile phones ─ a disruptive and often unwelcome behavior in most educational settings. Existing biofeedback devices (e.g., chest straps, clip-ons, inhalers) are similarly contextually inappropriate, making use obvious, distracting, and potentially stigmatizing. To overcome these barriers, the PI developed the AIRpen, a simple, affordable, multi-functional stress management device that is designed to fit into the fabric of users’ lives to potentially optimize the delivery, practice, and fidelity of diaphragmatic breathing (DB) interventions in real\u0002world settings. With anecdotal and empirical evidence supporting the device as feasible and acceptable in real\u0002world academic settings (Purdue IRB-2022-423), this Phase I STTR project proposes the following aims: Aim 1. Develop and refine the AIRpen intervention to enable the use of the device without oversight by a professional. Aim 2: Develop Smart AIRpen prototypes, which are equipped with sensors to measure user adherence in future real-world effectiveness studies. Aim 3: Establish the usability and acceptability of the AIRpen intervention with a sample of 60 college students (30 in each device group) in a laboratory setting and gather preliminary feedback on subject-reported stress using physiological and subjective surveys as a secondary outcome. Aim 4: Establish the feasibility of a future real-world research study that will evaluate the usability and acceptability of the AIRpen intervention when used during an exam period with a sample of 30 college students. Secondary outcome data utilizing subject-reported stress measures will also be collected. Results will support future larger-scale effectiveness trials and inform future protocol designs for scaling cost-effective and time-efficient treatments that broadly support the development of coping skills for stress management.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15149", "attributes": { "award_id": "2433784", "title": "Travel: Conference: Gateways 2024", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Computer and Information Science and Engineering (CISE)", "EDUCATION AND WORKFORCE" ], "program_reference_codes": [], "program_officials": [ { "id": 6428, "first_name": "Varun", "last_name": "Chandola", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": null, "award_amount": 32251, "principal_investigator": { "id": 13923, "first_name": "Sandra", "last_name": "Gesing", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 258, "ror": "", "name": "University of California-San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Gateways 2024 is the major event for the science gateway community in the US to discuss challenges and solutions in the area, to identify new issues, to shape future directions for research, foster the exchange of ideas, standards and common requirements and push towards the wider adoption of science gateways. The topics covered by the Gateways conference series range from technical topics to use cases to related content such as usability or sustainability of science gateways. The knowledge transfer can be transformative between different research domains and technical content. The building blocks of science gateway frameworks are re-usable in diverse research areas evident in widely used frameworks such as Hubzero and Tapis. The Gateways conference series sets the stage for learning, engaging and empowering the different stakeholders in the community who are science gateway users, developers and providers as well as funders and decision makers. Providing travel grants for students and early-career researchers allows to include a diverse audience and support underrepresented minorities.<br/><br/>Science gateways are a key part of NSF funded Cyberinfrastructure, and they are used by hundreds of thousands of researchers and students, supporting both publication-quality science and at-scale education. Science gateways involve a comprehensive set of research domains that has a broad impact on society, addressing considerable challenges such as pandemics, climate change, global sustainability of food, water, and land use driven by growing populations and rising per capita incomes. In recognition of their importance, NSF has funded the Science Gateways Community Institute (SGCI) and more recently the SGX3 Science Gateways Center of Excellence to provide leadership for the science gateways community. The Gateways conference series is one of the of flagships of SGCI and SGX3 and the major event in the US to bring the science gateways community together. The conference series has existed since 2016 and has attracted each year between 100-170 participants. In 2023 it has moved from an SGX3-organized conference to a community-driven conference with the first time the general chair being selected by a newly established advisory board for the conference and who is not part of the SGCI/SGX3 team. The goal is to attract additional research domains and tap into the chair's networks that are not already in contact with SGCI/SGX3. SGX3 continues to guide the conference while inviting each year since 2023 a different general chair. Gateways 2024 features various program formats such as keynotes, presentations, tutorials, demos, panels, posters and Bring Your Own Portal. Accepted submissions are published in open-access proceedings and accepted papers are invited to a special issue in a journal. SGCI/SGX3 has an impressive record of underrepresented minority involvement within the science gateway community. The travel grant allows to involve more students and early-career researchers at Gateways 2024 and they are selected under consideration of diversity, equity and inclusion.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15133", "attributes": { "award_id": "2414965", "title": "Instrument-free yes/no quantitative analysis of molecular biomarkers", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Engineering (ENG)", "Special Initiatives" ], "program_reference_codes": [], "program_officials": [ { "id": 961, "first_name": "Aleksandr", "last_name": "Simonian", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": null, "award_amount": 380074, "principal_investigator": { "id": 31692, "first_name": "Irina", "last_name": "Nesterova", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 574, "ror": "https://ror.org/012wxa772", "name": "Northern Illinois University", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Contemplating on the recent pandemics, the general public came to realize and appreciate the vital role of do-it-yourself diagnostic devices for disease control and management. Such devices report whether a unique pathogen-associate molecule (also known as a molecular biomarker) is found in a human. To extend the benefit of accessible molecular diagnostics to a wider range of diseases and situations, it is critical to develop devices that not only report whether a specific molecular biomarker is present but also answer the question of how much of that biomarker is present (so called quantitative analysis). The goal of this project is to develop a platform that enables an equipment-free and easy-to-interpret quantitative analysis of molecular biomarkers in do-it-yourself and point-of-care environments. To ensure an easy interpretation, the platform will produce a yes/no answer that involves observing bubbles as a readout. Observing bubbles does not require scientific training, an equipped lab, or color vision proficiency and, therefore, can be easily recognized by everyone ages 2 and up. In addition to public health benefits, the proposed development will spark and sustain a STEM interest in middle- and high school student through their direct hands-on engagement in the project- related experimental work.<br/><br/>The goal of this project is to develop a platform for instrument-free easy-to-interpret quantitative analysis of molecular biomarkers. The proposed platform will comprise two developments: a yes/no output for quantitative measurement and a novel equipment-free signal readout. The yes/no quantitative measurement will be enabled through stoichiometry. The heart of the model is negative cooperativity-based target – probe binding. The binding modality yields a well-defined structure exactly at the stoichiometric equivalence point. Detection of the structure is a yes/no event for a quantitative result. The new equipment-free readout will be based on bubbling produced in a gas-generating reaction. As an easy to spot and interpret phenomena, bubbling perfectly matches the yes/no paradigm. The gas-generating readout will be triggered via an activatable in the equivalence point catalytic system. The project will produce a general methodology that is adaptable to a range of molecular targets including potential new agents (once their target binding is characterized to some extent).<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15252", "attributes": { "award_id": "1S10OD034285-01A1", "title": "NAEOTOM Alpha Photon-Counting CT Scanner", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 25507, "first_name": "Xiang-Ning", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-15", "end_date": "2025-08-14", "award_amount": 2000000, "principal_investigator": { "id": 26633, "first_name": "ERIC Alfred", "last_name": "HOFFMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 220, "ror": "https://ror.org/036jqmy94", "name": "University of Iowa", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "This is a request to upgrade our current Siemens SOMATOM Force research energy integrating CT scanner to a newly released photon-counting CT scanner (Siemens NAEOTOM Alpha). While we have made great progress in the use of quantitative CT imaging to sub-phenotype lung disease there are limitations which this new scanner design will eliminate. Beam hardening is a scanning artifact which makes the lung appear less dense than it actually is. Because the new scanner directly counts every photon passing through the body and bins them into energy ranges, by reconstructing the lungs with a narrower photon range (selected for the kV range which best maximizes tissue contrast) will essentiall eliminate this error. Additionally, because the detection of photons is a digital process, the noise associated with analogue to digital conversion of light signals is eliminated, significantly reducing electronic noise. The spatial resolution is considerably higher and there is a choice of keeping similar dose as previous protocols (which have already been reduced nearly 10 fold) while taking advantage of the improved spatial resolution, or significanlty reducing the dose further and keep the same resolution. Because the photons are captured along with their energy characteristics, the photon count at each location can be binned into energy ranges, allowing for the seperation of multiple materials such as krypton and gadolinium for the simultaneous assessment of ventilation and perfusion. Additional contrast agents are under development to also, simultaneously, tag inflammation. Because of the improved contrast resolution, we will be able to further reduce the amount of contrast agent used by as much as 40%. We propose 9 major projects, all associated with either multi-center studies seeking new phenotypes of lung disease (COPD, Asthma, IPF, PASC (long COVID) etc. , or local investigations into lung pathologies. The scanner promises to improve the ability to assess airway wall thickness further into the lung periphery and to make possible the identification and seperation of arteries and veins.with similar abilities to extend to the lung periphery. Through deep learning and transfer learning, we propose that these improvement will help advance utility of existing scanner images as well. Because we are the radiology Center, the scanner not only allows us to take advantage of the advanced methodology locally, but we will be able to continue to disseminate newer protocols, keeping the lung community at imaging state-of-the-art. There are already 7 such scanners delivered to cinical centers within the US and this is expected to rapidly expand. Thus, the opportunity for research translation.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15233", "attributes": { "award_id": "1R21AI181677-01", "title": "Synergizing neutralization and non-neutralization antibody targets at the HIV/SIV viral spike apex", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 31817, "first_name": "Nancy R.", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-09", "end_date": "2026-06-30", "award_amount": 228825, "principal_investigator": { "id": 21421, "first_name": "TIMOTHY J", "last_name": "CARDOZO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "An HIV vaccine remains a critical and as yet unrealized asset in the 40-year fight against the HIV/AIDS pandemic. New insights towards achieving vaccine protection from HIV acquisition may be gained by a comparative case study of COVID-19 vaccines, which achieved nearly 100% efficacy against a similarly enveloped, RNA virus with a similarly architected, trimeric, Class I fusion viral spike mechanism. Neutralization B-cell epitopes exposed at the apex of the SARS-CoV-2 trimeric viral spike correlated clearly and strongly with protection from viral acquisition, both in humans in the real world/circulating virus setting and in non-human primate (NHP) preclinical models. We hypothesized that vaccine immunogens could be improved by focusing antibody responses to two equivalent B-cell epitopes at the HIV/SIV viral spike apex, one an epitope targeted by neutralizing antibodies (V2b) and one a purely non-neutralization epitope (V2c). In preliminary results, we showed that removal of the viral spike apical V1 loop segment (DV1-Env) masking the V2c epitope enhanced protection against viral challenge in both a highly stringent SIV and matched SHIV challenge model, achieving >90% vaccine efficacy. In further preliminary results, we designed an immunogen displaying only this V2c epitope in isolation and proved that it was highly immunogenic as an isolated epitope and indeed elicited purely non-neutralizing antibodies in vivo. The study revealed that V2c contributed to, but was not sufficient on its own, for protection. In this exploratory study, we pursue the new hypothesis that the combination of the two HIV, viral-spike apical, B-cell epitopes in a single vaccine can reconstitute an increased level of protection as observed with COVID-19 vaccines, by synergizing V2c with the V2b neutralization epitope. We will 1) design and validate a V2b-focused immunogen, and 2) test the precise combination of neutralizing, vaccine-elicited anti-V2b antibodies with non-neutralizing, cytotoxic, vaccine-elicited V2c antibodies, along with coordinated cellular immune responses in vivo for their ability to delay viral acquisition as compared to the V2c epitope alone. Successful results in these two aims could justify a research project on the design and translational development of a novel, viral-spike-apex-focused, efficacious HIV vaccine.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15248", "attributes": { "award_id": "1F31AI176851-01A1", "title": "Investigating the potential of wastewater surveillance data to improve SARS-CoV-2 dynamical modeling and forecasting", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6243, "first_name": "BROOKE ALLISON", "last_name": "Bozick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2026-07-31", "award_amount": 36053, "principal_investigator": { "id": 31835, "first_name": "Emma May", "last_name": "Gorin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Policy makers, researchers and public health officials rely on forecasts from infectious disease models to anticipate resource use, assess risk, and plan public health interventions. In order to effectively and accurately predict future cases and hospitalization rates of COVID-19, these models depend on high quality data on infections in the population. However, as clinical testing becomes less reliable with the ubiquity of at-home antigen tests and the frequency of case reporting is decreased in many states, there is a critical need to identify alternative data sources. Wastewater-based surveillance is a promising supplement to traditional data sources for monitoring infection at the population level: it is anonymous, cost-effective, and unaffected by variation in clinical testing and reporting. It also reflects infections in the population days or weeks sooner than they would be captured by reported cases or hospitalizations. While there is ample evidence that wastewater concentrations of SARS-CoV-2 correlate with COVID-19 cases, wastewater data have rarely been used to inform modeling and forecasting, and the benefit of incorporating wastewater surveillance data into data-driven dynamical models for forecasting has not been rigorously assessed. The goal of this project is to leverage a rich dataset from the New York State Wastewater Surveillance Network to evaluate the potential for wastewater surveillance data to improve inference of SARS-CoV-2 transmission dynamics. Partnering with the New York State Wastewater Surveillance Network, which includes over 150 wastewater treatment plants across 61 counties of New York State and represents a population of more than 15 million, provides a unique opportunity to investigate the value of wastewater surveillance for modeling at a larger scale. We will build on an existing metapopulation model developed by the Shaman Lab to test how inference and forecasting of transmission dynamics can be improved by integrating wastewater data. In other words, we will use retrospective data from New York State to rigorously assess: can we predict future cases more accurately by using wastewater data to inform our models? This study would be the first that we know of to use a metapopulation structure, which considers population movement, to model SARS-CoV-2 with wastewater surveillance data. By more realistically modeling how human populations move and mix, this model structure can better capture real-world transmission dynamics. This will be crucial to realistically evaluate whether wastewater data can be relied on in the future to forecast COVID-19 incidence, which will be particularly important as clinical testing fluctuates and case reporting becomes sparser. It may also motivate the application of wastewater-based modeling to other pathogens detectable in feces, facilitating the development of prompt, cost-effective forecasts of other communicable diseases in the future.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 2, "pages": 1424, "count": 14236 } } }